ChromaDex(US:CDXC)2025-05-07 21:30Financial Data and Key Metrics Changes - In Q1 2025, Niagen Bioscience reported revenues of $30.5 million, a 38% year-over-year increase, and net income of $5.1 million, compared to a net loss of $0.5 million in Q1 2024 [7][22] - The company generated $7.9 million in cash from operations, a significant increase from $0.3 million in the same period last year [22][23] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and supply chain cost savings [19][22] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [8][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8 million [8][18] - The Niagen plus product line, which includes intravenous and injection forms, is a key focus area, with availability in nearly 600 clinics nationwide [8][10] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company is actively monitoring the competitive landscape, noting that many NAD supplements on the market do not meet label claims [14] Company Strategy and Development Direction - Niagen Bioscience aims to position itself as the leader in NAD-boosting solutions, emphasizing scientific rigor, transparency, and integrity [16] - The company is focused on expanding its pharmaceutical applications, particularly in ongoing clinical studies for Parkinson's disease and ataxia telangiectasia [10][11] - The recent rebranding from ChromaDex to Niagen Bioscience aligns with its mission to promote healthy aging [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook from approximately 18% to a range of 20% to 25% [24][25] - The company is committed to operational discipline and efficiency, with expectations of steady gross margins and sustained profitability [25][26] Other Important Information - Niagen Bioscience has established a primarily U.S.-based supply chain, which remains unaffected by recent tariffs [20] - The company has received a new composition of matter patent, broadening its intellectual property portfolio [11] Q&A Session Summary Question: What are the emerging tailwinds for the adoption of the NIAGEN IV product lineup? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and positive feedback on its benefits compared to traditional NAD IV [28][29] Question: What new promotional strategies are expected for the e-commerce business? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers, but no aggressive campaigns are planned [33][34][36] Question: How many clinics are expected to adopt NIAGEN plus by the end of the year? - Management aims to have NIAGEN plus in 1,000 clinics by year-end, with a potential addressable market of 2,000 to 3,000 clinics [41][42] Question: What is the status of the injectable NIAGEN plus product? - The injectable product is currently offered in many clinics, with plans for an at-home version expected by Q4 2025 [72][73] Question: What is the status of discussions with the FDA regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received, indicating progress [88][89]